Skip to main content
main-content

Latest news stories

Latest news stories

01-17-2019 | Glucokinase activators | News

Hepatic glucokinase activation may improve glycemic control in type 2 diabetes

The hepatoselective glucokinase activator TTP399 reduces glycated hemoglobin levels without increasing the risk for hypoglycemia among patients with type 2 diabetes, suggest findings from the phase IIb AGATA trial.

Source:

Sci Transl Med 2019; doi:10.1126/scitranslmed.aau3441

01-16-2019 | Diabetes prevention | News

Observational data highlight importance of diabetes prevention in midlife

Individuals who maintain a blood glucose level below the diabetes threshold during middle age have a lower risk for cardiovascular disease than those who convert to diabetes during this time, observational study data show.

Source:

Diabetes Care 2019; doi:10.2337/dc18-1773

01-16-2019 | Obesity | News

Gastric bypass pros and cons reported for type 2 diabetes patients

Overweight and obese patients with type 2 diabetes who undergo gastric bypass have significantly lower risks for death, cardiovascular disease, and severe kidney disease than those who do not have such surgery, Swedish research shows.

Source:

BMJ Open 2019; doi:10.1136/bmjopen-2018-023882

01-14-2019 | Mental health | medwireNews | News

High mental illness burden in young-onset type 2 diabetes

Over a third of time spent in hospital before the age of 40 years by patients who develop type 2 diabetes by this age is due to mental illness, report researchers.

Source:

Ann Intern Med 2019; doi:10.7326/M18-1900

01-09-2019 | Nephropathy | News

Albuminuria backed as kidney disease treatment response marker

The results of two individual patient data meta-analyses support albuminuria as a surrogate marker of treatment response in patients with chronic kidney disease, particularly those with high baseline albuminuria.

Source:

Lancet Diabetes Endocrinol 2019; doi:10.1016/S2213-8587(18)30314-0
Lancet Diabetes Endocrinol 2019; doi:10.1016/S2213-8587(18)30313-9

01-08-2019 | Dapagliflozin | News

Observational data hint at additional dapagliflozin benefits

A real-world study based on DECLARE-TIMI 58 inclusion and outcome criteria shows that dapagliflozin not only reduces cardiovascular risk among patients with type 2 diabetes, in line with the original trial results, but may also lower all-cause mortality risk.

Source:

Diabetes Obes Metab 2019; doi:10.1111/dom.13627

01-07-2019 | Sitagliptin | News

Early sitagliptin initiation benefits patients uptitrating metformin

Patients with type 2 diabetes who are uptitrating to a maximum metformin dose benefit from improved glycemic control when they simultaneously initiate sitagliptin, randomized trial findings suggest.

Source:

Diabetes Obes Metab 2019; doi:10.1111/dom.13626

01-04-2019 | Sleep disorders | News

News in brief

Insomnia confers considerable type 2 diabetes risk

Insomnia bestows a degree of risk for type 2 diabetes on patients who already have prediabetes that “is similar to that conferred by traditional risk factors,” according to researchers.

01-03-2019 | Cardiovascular outcomes | News

Coronary artery calcification predicts coronary events in type 1 diabetes

The risk for coronary artery disease increases significantly with increasing levels of coronary artery calcification in individuals with type 1 diabetes, US researchers report.

Source:

Diabetologia 2018; doi:10.1007/s00125-018-4764-2

01-02-2019 | Canagliflozin | medwireNews | News

No fracture risk found with canagliflozin in real-world data

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

Source:

Ann Intern Med 2019; doi:10.7326/M18-0567
Ann Intern Med 2019; doi:10.7326/M18-3550

12-19-2018 | Older adults | News

News in brief

Type 2 diabetes may hasten cognitive decline

A prospective study reveals accelerated declines in some measures of cognitive performance among people with type 2 diabetes.

12-19-2018 | Insulin degludec | Highlight | News

Real-world data show benefits of insulin degludec vs glargine in type 2 diabetes

Insulin-naive adults with type 2 diabetes derive greater benefit from treatment with insulin degludec than from insulin glargine 300 units/mL, results from the US clinical practice-based CONFIRM study show.

Source:

Diabetes Obes Metab 2018; doi:10.1111/dom.13616

12-18-2018 | Pathophysiology | News

Pancreatic volume reductions occur early in diabetes disease process

Individuals with recently diagnosed type 1 diabetes, as well as their first-degree relatives, have significantly smaller pancreases than individuals with no history of diabetes, show two studies published in Diabetes Care.

Source:

Diabetes Care 2018; doi:10.2337/dc18-1507
Diabetes Care 2018; doi:10.2337/dc18-1512

12-14-2018 | Artificial pancreas systems | News

MD-Logic closed-loop system successful for unmonitored day and night use

The DREAM5 randomized trial has confirmed the efficacy of closed-loop insulin delivery with the MD-logic algorithm in adolescents and young adults without remote monitoring.

Source:

Diabetes Obes Metab 2018; doi:10.1111/dom.13585

12-13-2018 | Faster-acting insulin aspart | News

Fast-acting insulin aspart efficacy confirmed in CSII setting

Fast-acting insulin aspart is as effective as insulin aspart for glucose control when used for continuous subcutaneous insulin infusion in adults with type 1 diabetes, results of the onset 5 study show.

Source:

Diabet Obes Metab 2018; doi:10.1111/dom.13610

12-07-2018 | DPP-4 inhibitors | medwireNews | News

Possible bile duct cancer risk with incretin-based medications

Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.

Source:

BMJ 2018; 363: k4880
BMJ 2018; 363: k5155

12-07-2018 | Liraglutide (T2DM) | News

Liraglutide cardioprotection replicated in real-world data

Registry data from Denmark and Sweden uphold the cardioprotective effects of liraglutide observed in randomized trials, with the strongest effects seen in patients with established cardiovascular disease.

Source:

Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30320-6
Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30340-1

12-07-2018 | Pregnancy | News

Metformin plus lifestyle advice does not improve pregnancy outcomes for obese women

Giving pregnant obese women metformin in addition to dietary and lifestyle advice does not reduce the likelihood of them having a baby with a high birthweight, show the results of the GRoW randomized trial.

Source:

Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30337-1
Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30310-3

12-05-2018 | Empagliflozin | News

Empagliflozin beneficial for uncontrolled nocturnal hypertension

The addition of empagliflozin reduces nighttime blood pressure in older diabetes patients who have nocturnal hypertension despite medication including angiotensin receptor blockers, show findings from a randomized trial.

Source:

Circulation 2018; doi:10.1161/CIRCULATIONAHA.118.037076

12-03-2018 | Liraglutide (T2DM) | medwireNews | News

Older type 2 diabetes patients may derive greatest liraglutide benefits

The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.

Source:

Ann Intern Med 2019; doi:10.7326/M18-1569

image credits